Performance
LowHasn't fared well - amongst the low performers
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
—
—
—
Combat Drugs is engaged in manufacturing and trading of pharmaceuticals products
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
Decipher Labs Ltd - 524752 - Board Meeting Outcome for Outcome Of Board Meeting For The Quarter 30.09.2024 Under Regulation 30 And 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015. | Download
Decipher Labs Ltd - 524752 - Board Meeting Outcome for Outcome Of Board Meeting For The Quarter 30.09.2024 Under Regulation 30 And 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015. | Download
Decipher Labs Ltd - 524752 - Board Meeting Intimation for Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2024. | Download
Decipher Labs Ltd - 524752 - Board Meeting Intimation for Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2024. | Download
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant